Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IBI 3005

Next Previous
Drug Profile

IBI 3005

Alternative Names: IBI-3005

Latest Information Update: 03 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Innovent Biologics
  • Class Antineoplastics; Bispecific antibodies; Camptothecins; Drug conjugates; Immunoconjugates; Immunotherapies
  • Mechanism of Action DNA topoisomerase I inhibitors; Hypoxia-inducible factor 1 alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 01 Jun 2026 Innovent Biologics plans a phase I/II trial for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent, Combination therapy) in China (Parenteral, Injection) in June 2026 (NCT07612137)
  • 08 Jan 2025 Phase-I clinical trials in Solid tumours (Metastatic disease, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in China (Parenteral)
  • 22 May 2024 Innovent Biologics plans a phase I trial in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease) (NCT06418061)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top